- ISIN
- US35473P5200
- CUSIP
- 35473P520
- Issuer
- Franklin Templeton
- Inception Date
- Feb 25, 2020
- Region
- Developed Markets (Broad)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- No Index (Active)
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Multi-Cap
- Asset Class Style
- Growth
- Assets Under Management
- $24M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
HELX Performance Chart
Franklin Genomic Advancements ETF (HELX) is up 0.1% since the beginning of the year. HELX is currently trading at $36 per share. Investors who bought $1,000 worth of HELX shares 5 years ago would now be looking at an investment worth $766.
Loading charts...
Returns By Period
Franklin Genomic Advancements ETF (HELX) has returned 0.05% so far this year and 33.73% over the past 12 months.
Franklin Genomic Advancements ETF
- 1D
- -0.45%
- 1M
- 6.20%
- YTD
- 0.05%
- 6M
- -2.14%
- 1Y
- 33.73%
- 3Y*
- 6.84%
- 5Y*
- -5.20%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
HELX Monthly Returns History
Based on dividend-adjusted daily data since Feb 27, 2020, HELX's average daily return is +0.04%, while the average monthly return is +0.79%. At this rate, an investment would double in approximately 7.3 years.
Historically, 56% of months were positive and 44% were negative. The best month was Apr 2020 with a return of +20.6%, while the worst month was Jan 2022 at -19.4%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.
On a daily basis, HELX closed higher 52% of trading days. The best single day was Apr 9, 2025 with a return of +8.2%, while the worst single day was Mar 12, 2020 at -9.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.48% | -5.31% | -4.31% | 1.05% | 6.08% | 2.53% | 0.05% | ||||||
| 2025 | 6.39% | -4.65% | -7.73% | 0.89% | -4.95% | 7.03% | 0.27% | 7.44% | 3.66% | 13.90% | 7.96% | -4.23% | 26.34% |
| 2024 | -2.26% | 7.99% | 1.86% | -8.22% | 3.24% | 2.07% | 6.17% | -1.06% | -2.61% | -6.77% | 2.62% | -6.97% | -5.32% |
| 2023 | 5.36% | -6.27% | 2.13% | -1.77% | -1.09% | 2.42% | 3.31% | -1.45% | -7.95% | -10.04% | 9.30% | 9.36% | 1.14% |
| 2022 | -19.37% | -3.80% | -1.88% | -11.81% | 2.46% | -3.95% | 10.57% | -9.41% | -7.59% | 4.30% | 3.31% | -5.72% | -37.89% |
| 2021 | 8.19% | -6.00% | -3.73% | 6.47% | -5.43% | 18.63% | 2.50% | 5.69% | -6.74% | 1.73% | -6.03% | -2.78% | 9.80% |
Benchmark Metrics
Franklin Genomic Advancements ETF has an annualized alpha of -3.92%, beta of 0.90, and R2 of 0.46 versus S&P 500 Index. Calculated based on daily prices since February 27, 2020.
- This ETF participated in 123.37% of S&P 500 Index downside but only 94.79% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.46 means the benchmark explains less than half of this ETF's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- -3.92%
- Beta
- 0.90
- R²
- 0.46
- Upside Capture
- 94.79%
- Downside Capture
- 123.37%
Expense Ratio
HELX has an expense ratio of 0.50%, placing it in the medium range.
Return for Risk
Risk / Return Rank
HELX ranks 42 for risk / return — on par with similar ETFs. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Franklin Genomic Advancements ETF (HELX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HELX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.44 | ||
| Sortino ratioReturn per unit of downside risk | -0.47 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.37 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 1.88 | 2.78 | -0.90 |
| Martin ratioReturn relative to average drawdown | 4.77 | 12.44 | -7.67 |
Dividends
Dividend History
Franklin Genomic Advancements ETF provided a 0.39% dividend yield over the last twelve months, with an annual payout of $0.14 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Dividend | $0.14 | $0.14 | $0.00 | $0.00 | $0.00 | $0.12 | $0.05 |
Dividend yield | 0.39% | 0.39% | 0.00% | 0.00% | 0.00% | 0.24% | 0.12% |
Monthly Dividends
The table displays the monthly dividend distributions for Franklin Genomic Advancements ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.14 | $0.14 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.12 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Franklin Genomic Advancements ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Franklin Genomic Advancements ETF was 58.75%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Franklin Genomic Advancements ETF drawdown is 37.22%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -58.75%Apr 2025 | 3y 7mo | — | 4y 9moSep 2021 - now |
COVID crash2020 | -27.15%Mar 2020 | 11d | 1mo 12d | 1mo 23dMar 2020 - Apr 2020 |
2021 bear market2021 | -26.01%Mar 2021 | 20d | 4mo 24d | 5mo 14dFeb 2021 - Jul 2021 |
2020 pullback2020 | -8.87%Sep 2020 | 5d | 27d | 1mo 2dSep 2020 - Oct 2020 |
2020 pullback2020 | -8.01%Nov 2020 | 19d | 3d | 22dOct 2020 - Nov 2020 |
Drawdown Indicators
| HELX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -58.75% | -56.78% | -1.97% |
Max Drawdown (1Y)Largest decline over 1 year | -18.01% | -9.10% | -8.91% |
Max Drawdown (3Y)Largest decline over 3 years | -29.48% | -18.90% | -10.58% |
Max Drawdown (5Y)Largest decline over 5 years | -58.75% | -25.43% | -33.32% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -37.22% | -1.80% | -35.42% |
Average DrawdownAverage peak-to-trough decline | -34.33% | -10.71% | -23.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.09% | 2.03% | +5.06% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with HELX
Add Franklin Genomic Advancements ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with HELX